非透明细胞肾细胞癌最佳治疗的探索:比较VEGFR-TKI与mTOR抑制剂靶向治疗的随机临床试验Meta分析
该Meta分析纳入4项随机对照试验、332例可评估PFS的非透明细胞肾细胞癌患者,比较VEGFR-TKI与mTOR抑制剂的疗效。结果显示TKI较mTOR抑制剂显著降低进展风险(HR=0.71,95%CI 0.60-0.84,p<0.0001),但OS无显著差异(HR=0.86,95%CI 0.67-1.12,p=0.27),ORR亦无显著改善(RR=2.21,95%CI 0.87-5.60,p=0.09)。
要点
- TKI较mTOR抑制剂显著降低非透明细胞肾细胞癌患者的进展风险(HR=0.71,95%CI 0.60-0.84,p<0.0001)。
- 一线舒尼替尼较依维莫司显著降低进展风险(HR=0.67,95%CI 0.56-0.80,p<0.00001)。
- TKI与mTOR抑制剂的OS及ORR均无显著差异。
核心结论
- 与mTOR抑制剂相比,TKI治疗显著改善PFS但不改善OS。
- 舒尼替尼一线治疗较依维莫司降低进展风险,支持广泛用于ccRCC的标准治疗范式。
- 现有靶向治疗疗效相对有限,凸显未来基于组织学和分子驱动治疗范式的需求。
研究设计与样本
- 检索MEDLINE/PubMed、Cochrane图书馆及美国临床肿瘤学会会议摘要,纳入前瞻性研究。
- 按PRISMA声明进行数据提取。
- 最终纳入4项随机对照试验,共332例患者可评估PFS。
主要发现
- TKI较mTOR抑制剂显著降低进展风险(HR=0.71,95%CI 0.60-0.84,p<0.0001)。
- 一线舒尼替尼较依维莫司显著降低进展风险(HR=0.67,95%CI 0.56-0.80,p<0.00001)。
- 332例可评估OS患者中,TKI与mTOR抑制剂无显著差异(HR=0.86,95%CI 0.67-1.12,p=0.27)。
- 176例可评估ORR患者中,TKI未改善ORR(RR=2.21,95%CI 0.87-5.60,p=0.09),但舒尼替尼使肿瘤缓解概率翻倍。
关键数值与推荐
- PFS:TKI vs mTOR抑制剂,HR=0.71(95%CI 0.60-0.84,p<0.0001)。
- 一线舒尼替尼 vs 依维莫司PFS:HR=0.67(95%CI 0.56-0.80,p<0.00001)。
- OS:TKI vs mTOR抑制剂,HR=0.86(95%CI 0.67-1.12,p=0.27)。
- ORR:TKI vs mTOR抑制剂,RR=2.21(95%CI 0.87-5.60,p=0.09)。
临床怎么用
- 作者认为,舒尼替尼一线治疗较依维莫司降低进展风险,支持广泛用于ccRCC患者的标准治疗范式。
- 作者指出,现有靶向治疗疗效相对有限,凸显未来基于组织学和分子驱动治疗范式的需求。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Non-clear cell renal cell carcinoma (nccRCC) tumours include a heterogeneous group of malignancies that profoundly differ in terms of morphology, genetic profile, clinical behaviour and prognosis. The optimal treatment algorithm for nccRCC is still unknown and derived mainly from evidence available for ccRCC, being therefore represented by targeted agents against vascular endothelial growth factor and mammalian target of rapamycin (mTOR) pathways. We aimed to compare the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKis) and mTOR inhibitors (mTORi) for the treatment of nccRCC patients. METHODS: Searching the MEDLINE/PubMed, Cochrane Library and American Society of Clinical Oncology Meeting abstracts prospective studies were identified. Data extraction was conduced according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. The measured outcomes were progression-free survival (PFS), overall survival (OS) and the overall response rate (ORR). RESULTS: Four randomised controlled trials were selected for final analysis, with a total of 332 patients evaluable for PFS. Treatment with TKi significantly reduced the risk of progression compared with mTORi (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.60-0.84; p < 0.0001). This difference remained significant when sunitinib was compared with everolimus in first-line setting (HR = 0.67; 95% CI, 0.56-0.80; p < 0.00001). In the 332 patients evaluable for OS, no significant difference was found between TKi and mTORi (HR = 0.86; 95% CI, 0.67-1.12; p = 0.27). In the 176 evaluable patients, TKis therapy did not improve the ORR when compared with mTORi (relative risk [RR] = 2.21; 95% CI, 0.87-5.60; p = 0.09), even if treatment with sunitinib doubled the probability of achieving a tumour response. CONCLUSIONS: Treatment with TKis significantly improves PFS, but not OS, when compared with mTORi. Moreover, sunitinib as first-line therapy reduces the risk of progression compared with everolimus; therefore, supporting the standard treatment paradigm broadly used for ccRCC patients. The relatively modest efficacy of available targeted therapies reinforces the need of future histology based, molecular driven therapeutic paradigm.
引用
- Ciccarese C, Iacovelli R, Brunelli M, et al. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer. 2017. PMID: 28756136. doi:10.1016/j.ejca.2017.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。